NL-OMON34234已完成3 期
A randomized, open label, multicentre trial to define the most effective haemoglobin concentration to start erythropoietin beta (neoRecormon) therapy in anaemic subjects with lymphoproliferative malignancy receiving chemotherapy *REPOS Study* - Repos study
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with lymphoproliferative malignancy i.e. multipel myeloma, chronic lymphocytic leukemia, non hodgkins lymphoma and hodgkins lymphoma who will be treated with chemotherapy which may induce anaemia
排除标准
- •transfusions or red bloodcells during the 2 weeks immediately prior to randomisation or rHuEPO within 12 weeks before inclusion
研究者
相似试验
进行中（未招募）
不适用
A randomized, open label, multicentre trial to define the most effective haemoglobin concentration to start erythropoietin beta (neoRecormon) therapy in anaemic subjects with lymphoproliferative malignancy receivin chemotherapyREPOSstudy - Repos studyAnemia in cancer patientsEUCTR2006-003727-37-NLHaga Teaching Hospital150
招募中
2 期
Safety and Efficacy of Eculizumab to prevent antibody mediated rejection in sensitized kidney transplant recipients from a deceased donorkidney transplantRenal and Urogenital - Kidney diseaseACTRN12612000333819Alexion Pharmaceuticals Inc40
招募中
2 期
Safety & Efficacy of Eculizumab to Prevent antibody mediated rejection in Living Donor Kidney Transplant Recipients Requiring DesensitizatioKidney transplantRenal and Urogenital - Kidney diseaseACTRN12611000880943Alexion Pharmaceuticals Australasia Pty Ltd80
进行中（未招募）
1 期
Study to assess the long-term safety, tolerability and efficacy the in pediatric patients of age 6 to less than 18 years, with moderate to severe chronic plaque psoriasisPlaque PsoriasisEUCTR2017-004515-39-PLovartis Pharma AG84
进行中（未招募）
1 期
Study to assess the long-term safety, tolerability and efficacy the in pediatric patients of age 6 to less than 18 years, with moderate to severe chronic plaque psoriasisPlaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2017-004515-39-CZovartis Pharma AG84